NEA Management Company
Latest statistics and disclosures from NEA Management Company's latest quarterly 13F-HR filing:
- Top 5 stock holdings are COUR, ACLX, RYTM, SVRA, VRNA, and represent 54.45% of NEA Management Company's stock portfolio.
- Added to shares of these 7 stocks: KRRO (+$41M), SYBX (+$10M), PHAT (+$6.2M), MYND, IKNA, ADXN, GOSS.
- Started 3 new stock positions in ADXN, MYND, KRRO.
- Reduced shares in these 6 stocks: MIRM (-$69M), Minerva Surgical (-$5.7M), Addex Therapeutics, SRFM, Eargo Inc - US, AKTX.
- Sold out of its positions in Addex Therapeutics, AKTX, Eargo Inc - US, Minerva Surgical, MIRM.
- NEA Management Company was a net seller of stock by $-15M.
- NEA Management Company has $1.5B in assets under management (AUM), dropping by 15.88%.
- Central Index Key (CIK): 0001512848
Tip: Access up to 7 years of quarterly data
Positions held by NEA Management Company consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for NEA Management Company
NEA Management Company holds 44 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Coursera (COUR) | 16.6 | $249M | 13M | 19.37 |
|
|
| Arcellx Common Stock (ACLX) | 13.9 | $208M | 3.7M | 55.50 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 8.9 | $134M | 2.9M | 45.97 |
|
|
| Savara (SVRA) | 7.7 | $115M | 25M | 4.70 |
|
|
| Verona Pharma Sponsered Ads (VRNA) | 7.4 | $111M | 5.1M | 21.73 |
|
|
| Crispr Therapeutics Namen Akt (CRSP) | 6.6 | $99M | 1.6M | 62.60 |
|
|
| CVRX (CVRX) | 5.0 | $75M | 2.4M | 31.44 |
|
|
| Geron Corporation (GERN) | 3.2 | $48M | 23M | 2.11 |
|
|
| Monte Rosa Therapeutics (GLUE) | 2.9 | $44M | 7.7M | 5.65 |
|
|
| Korro Bio (KRRO) | 2.7 | $41M | NEW | 1.1M | 38.34 |
|
| Nextnav Common Stock (NN) | 2.4 | $36M | 8.2M | 4.45 |
|
|
| Aurinia Pharmaceuticals (AUPH) | 2.4 | $36M | 4.0M | 8.99 |
|
|
| Nkarta (NKTX) | 1.6 | $24M | 3.6M | 6.60 |
|
|
| Bright Health Group Com New (NEUE) | 1.3 | $20M | 2.7M | 7.28 |
|
|
| Sagimet Biosciences Com Ser A (SGMT) | 1.3 | $19M | 3.9M | 4.88 |
|
|
| Celcuity (CELC) | 1.2 | $18M | 1.3M | 14.57 |
|
|
| Phathom Pharmaceuticals (PHAT) | 1.2 | $18M | +53% | 2.0M | 9.13 |
|
| Allakos (ALLK) | 1.1 | $17M | 6.1M | 2.73 |
|
|
| ZeroFox Holdings (ZFOX) | 1.0 | $16M | 18M | 0.87 |
|
|
| Trevi Therapeutics (TRVI) | 1.0 | $15M | 11M | 1.34 |
|
|
| Gossamer Bio (GOSS) | 1.0 | $15M | 16M | 0.91 |
|
|
| Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.9 | $14M | 17M | 0.79 |
|
|
| X4 Pharmaceuticals (XFOR) | 0.8 | $13M | 15M | 0.84 |
|
|
| Black Diamond Therapeutics (BDTX) | 0.8 | $13M | 4.4M | 2.81 |
|
|
| Tuya Sponsered Ads (TUYA) | 0.8 | $11M | 4.9M | 2.30 |
|
|
| Synlogic Com New (SYBX) | 0.7 | $11M | +936% | 2.9M | 3.85 |
|
| Glycomimetics (GLYC) | 0.7 | $11M | 4.8M | 2.36 |
|
|
| Desktop Metal Com Cl A (DM) | 0.7 | $11M | 14M | 0.75 |
|
|
| Inozyme Pharma (INZY) | 0.7 | $10M | 2.4M | 4.26 |
|
|
| Champions Oncology Com New (CSBR) | 0.6 | $9.6M | 1.7M | 5.62 |
|
|
| Reneo Pharmaceuticals (RPHM) | 0.5 | $7.7M | 4.8M | 1.60 |
|
|
| Inventiva Sa Ads (IVA) | 0.4 | $6.6M | 1.5M | 4.52 |
|
|
| Marker Therapeutics Com New (MRKR) | 0.4 | $5.9M | 1.1M | 5.50 |
|
|
| Buzzfeed Class A Com (BZFD) | 0.3 | $3.8M | 15M | 0.25 |
|
|
| Lexicon Pharmaceuticals Com New (LXRX) | 0.2 | $3.6M | 2.4M | 1.53 |
|
|
| Senti Biosciences Ord (SNTI) | 0.2 | $2.9M | 4.4M | 0.66 |
|
|
| Affimed Therapeutics B V | 0.2 | $2.8M | 4.4M | 0.62 |
|
|
| Regulus Therapeutics | 0.2 | $2.5M | 1.9M | 1.28 |
|
|
| Mynd Ai Spon Ads (MYND) | 0.1 | $1.8M | NEW | 24M | 0.08 |
|
| Acrivon Therapeutics Common Stock (ACRV) | 0.1 | $1.3M | 430k | 2.99 |
|
|
| Ikena Oncology (IKNA) | 0.1 | $1.1M | +214% | 570k | 1.97 |
|
| Wheels Up Experience Com Cl A (UP) | 0.0 | $364k | 106k | 3.43 |
|
|
| Surf Air Mobility (SRFM) | 0.0 | $307k | -50% | 220k | 1.40 |
|
| Addex Therapeutics Sponsored Ads (ADXN) | 0.0 | $306k | NEW | 9.0k | 33.97 |
|
Past Filings by NEA Management Company
SEC 13F filings are viewable for NEA Management Company going back to 2010
- NEA Management Company 2023 Q4 filed Feb. 14, 2024
- NEA Management Company 2023 Q3 filed Nov. 14, 2023
- NEA Management Company 2023 Q2 filed Aug. 11, 2023
- NEA Management Company 2023 Q1 filed May 15, 2023
- NEA Management Company 2022 Q4 filed Feb. 10, 2023
- NEA Management Company 2022 Q3 filed Nov. 14, 2022
- NEA Management Company 2022 Q2 filed Aug. 15, 2022
- NEA Management Company 2022 Q1 filed May 16, 2022
- NEA Management Company 2021 Q4 filed Feb. 14, 2022
- NEA Management Company 2021 Q3 filed Nov. 12, 2021
- NEA Management Company 2021 Q2 filed Aug. 2, 2021
- NEA Management Company 2021 Q1 filed May 14, 2021
- NEA Management Company 2020 Q4 filed Feb. 16, 2021
- NEA Management Company 2020 Q3 filed Nov. 6, 2020
- NEA Management Company 2020 Q2 filed Aug. 5, 2020
- NEA Management Company 2020 Q1 filed May 6, 2020